MetaCap

Apollomics (APLM) vs RenovoRx (RNXT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

RenovoRx (RNXT) has outperformed Apollomics (APLM) over the past year, gaining 18.3% versus a gain of 7.4%. Over five years, RNXT leads with a -85.3% price change compared with -98.4% for APLM. RenovoRx is the larger company by market cap ($45.5 million vs $45.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APLM+7.43%RNXT+18.34%
+228%+103%-23%
Nov 21, 20251 yearNov 20, 2026
APLM-98.43%RNXT-85.26%
+157%+22%-112%
Nov 22, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APLM versus RNXT key metrics
MetricAPLMRNXT
Share price$15.54$0.942
Market cap$45.28M$45.45M
1-day change-6.92%-10.29%
YTD return-16.90%+12.14%
1-year return+7.43%+18.34%
5-year return-98.43%-85.26%
EPS (TTM)$-0.25$-0.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$1.12M
Revenue growth (YoY)—+2511.63%
Net income (latest FY)$-53.86M$-11.17M
Gross margin—70.88%
Operating margin—-1113.98%
Net margin—-994.48%
52-week high$28.29$2.59
52-week low$12.58$0.77
Distance from 52-week high-45.09%-63.63%
Analyst consensus—none
Avg. price target upside—+656.90%
Average volume11.07K815.75K
Shares outstanding2.91M48.25M
Employees1417
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RNXT has outperformed APLM by 10.9 percentage points over the past year.

About Apollomics

APLM stock →

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

About RenovoRx

RNXT stock →

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

APLM vs RNXT FAQ

Which is bigger, Apollomics or RenovoRx?

RenovoRx (RNXT) is larger, with a market capitalization of $45.45M compared with $45.28M for Apollomics (APLM).

Which stock has performed better over the past year, APLM or RNXT?

RNXT returned +18.34% over the past 12 months, compared with +7.43% for APLM (price return, excluding dividends). Past performance does not predict future results.

Are Apollomics and RenovoRx in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons